Docoh
Loading...

Fri. 5 Nov 2021, 6:02am ETBenzinga
In: News, Price Target, Analyst Ratings
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $55 to $48.